Sustained Remission in Patients with Primary Immune Thrombocytopenia after Romiplostim Tapering and Discontinuation: A Case Series in Real Life Management in Spain

Romiplostim, a thrombopoietin-receptor agonist (TPO-ra), is a highly effective option in primary immune thrombocytopenia (ITP), with 80–90% of patients achieving platelet responses after few weeks of treatment. The evidence showing remissions, that is, sustained platelet counts after romiplostim dis...

Descripción completa

Detalles Bibliográficos
Autores principales: Mingot-Castellano, María-Eva, Grande-García, Carlos, Valcárcel-Ferreiras, David, Conill-Cortés, Clara, de Olivar-Oliver, Loreto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485313/
https://www.ncbi.nlm.nih.gov/pubmed/28695025
http://dx.doi.org/10.1155/2017/4109605

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485313/
https://www.ncbi.nlm.nih.gov/pubmed/28695025
http://dx.doi.org/10.1155/2017/4109605

Ejemplares similares